CLINICAL ROLE -
Medically Integrated Dispensing Service Best Practices
Practical Challenges in Switching to CDK4/6 Inhibitors
The Efficacy and Safety of CDK4/6 Inhibitors
Roles of the Oncologist Versus Pharmacist
Multidisciplinary Approach to Managing Oral Oncolytics
The Advent of Oral Oncolytics and Patient Access
Vertical Integration and Looking Toward the Future
Impact of Competition on Pricing in the Future
Factors Determining Inclusion of Biosimilars on the Formulary
Educating the Patient and Providers on Biosimilars
Role of Specialty Pharmacy Regarding Biosimilars
Challenges for Payers With Costs of Biosimilars
Pricing of Biosimilars With Biologics and Other Biosimilars
Regulatory and Legislative Impact on Biosimilars
Progress of Biosimilars and Personal Experience
Overview and Common Misunderstandings of Biosimilars
Shortage Effects on Clinical Trials and Future Hopes
Incentive Programs and Choosing a Manufacturer
Structural Overview of Supply Maintenance
The FDASIA Mandate and Interdisciplinary Communication
Palliative Fixes, Drug Essentiality, and Collateral Effects
The Risks of Drug Shortages & Timeline for Resupply
Choosing a Post-Shortage Solution and Preventive Budgeting
Unexpected Benefits and Personal Responses to Drug Shortages
Generic/Brand Drug Shortages & Medical Professional Impact
Supply-Chain Communication and Drug Reallocation
Typical Causes of Drug Shortages
Prevalence of Drug Shortage Today and Community Awareness
Innovative Developments in Specialty Therapeutic Areas
Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses specialty areas experiencing innovative developments in therapies.
How Does Launching a Personalized Drug Differ from Other Specialty Drugs?
Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.
